RxDoctor Payments Data

Dong Kim, MD

Radiation Oncology · Nashville, TNNPI 1861422420

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $895 of the $1,258 with a category attached, or 71.2%. Accuray Incorporated accounts for 75.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $947 and has fallen 95.2% since, to $45 in 2025.

$1,258in general payments, 2019–2025

Across 9 payments — averaging $139.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accuray Incorporated$947
  • Reflexion Medical, Inc.$213
  • Beone Medicines USA, Inc.$45
  • Beigene USA, Inc.$32
  • Johnson & Johnson$21

What the payments were for

  • Travel & lodging$36329%
  • Food & beverage$89571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,258 in reported general payments places this provider in the 70th percentile of 115 radiation oncology providers in Tennessee.

See all radiation oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$323,872
Medicare patients
237
Services billed
3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix19$49,345
Sucralfate12$1,880
Tamsulosin Hcl13$298
Nystatin15$289
Mometasone Furoate12$271
Dexamethasone16$211
Lidocaine Hcl ViscousLidocaine Hcl15$200
Silver Sulfadiazine11$142

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →